Sorry, this section is only available in Japanese.
著者 (34件)：
資料名：
巻： 109 号： 5 ページ： 1731-1737 発行年： 2018年
JST資料番号： U0505A ISSN： 1349-7006 資料種別： 逐次刊行物 (A)
記事区分： 解説 発行国： アメリカ合衆国 (USA) 言語： 英語 (EN)
前のページに戻る
この文献は全文を取り寄せることができます
JDreamⅢ複写サービスから文献全文の複写（冊子体のコピー）をお申込みできます。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
既に、G-Searchデータベースサービスまたは、JDreamⅢのIDをお持ちの方
JDreamⅢ複写サービスのご利用が初めての方
取り寄せる文献のタイトルと詳細
文献
J-GLOBAL ID：201802287056264007
整理番号：18A1053083
日本における希少がんの治療開発の現状と改善のための提案
Current state of therapeutic development for rare cancers in Japan, and proposals for improvement
Kawai Akira
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Kawai Akira
(Department of Musculoskeletal Oncology and Rehabilitation, Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan)
,
Goto Toshio
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Goto Toshio
(Program for Drug Discovery and Medical Technology Platforms, RIKEN, Tsukuba, Japan)
,
Shibata Tatsuhiro
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Shibata Tatsuhiro
(Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan)
,
Tani Kenzaburo
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Tani Kenzaburo
(Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)
,
Mizutani Shuki
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Mizutani Shuki
(Tokyo Medical and Dental University, Tokyo, Japan)
,
Nishikawa Akiyoshi
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Nishikawa Akiyoshi
(Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan)
,
Shibata Taro
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Shibata Taro
(Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan)
,
Matsumoto Seiichi
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Matsumoto Seiichi
(Sarcoma Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan)
,
Nagata Kyosuke
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Nagata Kyosuke
(University of Tsukuba, Tsukuba, Japan)
,
Narukawa Mamoru
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Narukawa Mamoru
(Department of Clinical Medicine (Pharmaceutical Medicine), School of Pharmacy, Kitasato University, Sagamihara, Japan)
,
Matsui Shigeyuki
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Matsui Shigeyuki
(Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan)
,
Ando Masashi
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Ando Masashi
(Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagakute, Japan)
,
Toguchida Junya
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Toguchida Junya
(Institute for Frontier Life and Medical Sciences/Center for iPS Cell Research and Application, Kyoto University, Tokyo, Japan)
,
Monden Morito
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Monden Morito
(Sakai City Hospital Organization, Sakai, Japan)
,
Heike Toshio
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Heike Toshio
(Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan)
,
Kimura Shinya
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Kimura Shinya
(Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan)
,
Ueda Ryuzo
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Ueda Ryuzo
(Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan)
資料名：
Cancer Science (Web)
(Cancer Science (Web))
巻： 109 号： 5 ページ： 1731-1737 発行年： 2018年
JST資料番号： U0505A ISSN： 1349-7006 資料種別： 逐次刊行物 (A)
記事区分： 解説 発行国： アメリカ合衆国 (USA) 言語： 英語 (EN)
JDreamⅢ複写サービスとは
JDreamⅢ複写サービスは、学術文献の全文を複写（コピー）して取り寄せできる有料サービスです。インターネットに公開されていない文献や、図書館に収録されていない文献の全文を、オンラインで取り寄せることができます。J-GLOBALの整理番号にも対応しているので、申し込みも簡単にできます。全文の複写（コピー）は郵送またはFAXでお送りします
※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。
※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。